PolicyRSSToday
A large survey in the U.K. found that most people—including families of babies screened for SMA, people living with SMA, doctors, and the general public—strongly support newborn screening for spinal muscular atrophy. The main reason people liked the idea was that catching SMA early could help babies have better health outcomes. Researchers looked at what factors influenced people's opinions about this type of screening.
WHY IT MATTERSIf newborn SMA screening becomes standard in the U.K., babies diagnosed early could start treatment sooner, potentially preventing severe muscle weakness and improving their long-term quality of life.
AdvocacyRSS2 days ago
The PBC Foundation International Summit is a conference where people living with primary biliary cholangitis (PBC)—a rare liver disease—share their experiences and perspectives. Unlike typical medical conferences focused mainly on doctors and research, this summit puts patients' voices at the center of discussions. A woman with PBC explains what makes this event different and valuable for the community.
WHY IT MATTERSPatient-centered conferences like this one help people with PBC connect with others, learn directly from their peers' experiences, and ensure their needs shape future research and treatment discussions.
AdvocacyRSS2 days ago
This article uses the excitement of NASA's Artemis II space mission as inspiration to encourage big dreams about finding a cure for pulmonary hypertension, a serious lung disease that affects blood vessels. The author draws a parallel between humanity's ability to reach for the stars and the hope that patients with pulmonary hypertension should have for breakthrough treatments. The piece is motivational rather than reporting on specific medical news or research developments.
WHY IT MATTERSThis article may resonate emotionally with pulmonary hypertension patients by framing their disease journey within a larger narrative of human achievement and possibility, though it does not announce any new treatments, trials, or clinical developments.
PolicyRSSApr 13
The FDA sent reminders to over 2,200 companies and research groups telling them they must share their clinical trial results on a public website called ClinicalTrials.gov. This is a requirement, not optional. The FDA is making sure that information about how medical treatments work—whether they help patients or cause problems—gets shared publicly so everyone can see the results.
WHY IT MATTERSWhen companies hide negative trial results, patients may not know the full picture about whether a treatment actually works, which could affect decisions about whether to participate in a trial or use a medication.
PolicyBIORXIVApr 10
Researchers created a standard naming and classification system for rare diseases to help doctors and scientists share information more easily across different countries. Right now, rare diseases aren't well organized in medical databases, which makes it hard to collect data and help patients. This new system aims to fix that problem so patients can be recognized and tracked better worldwide.
WHY IT MATTERSStandardized rare disease terminology means your diagnosis is more likely to be recognized consistently across different hospitals and countries, improving your chances of being included in research studies and getting accurate care.
PolicyPUBMEDApr 1
A European network for rare connective tissue diseases has created a new model where patients are treated as equal partners in research and care decisions. Instead of doctors alone deciding what to study and how to treat patients, this network includes patients in every step—from identifying problems to writing research papers together. This approach helps address long diagnostic delays and gaps in care that patients with these rare diseases often face.
WHY IT MATTERSPatients with rare connective tissue diseases can now directly influence research priorities and treatment approaches through structured partnership roles, rather than having decisions made without their input.
PolicyPUBMEDApr 1
Researchers compared how quickly rare disease drugs become available in China versus the United States between 2001 and 2024. The study looked at a problem called 'drug loss' — when medicines are approved in the US but never reach Chinese patients — and 'drug lag' — when there's a long delay before Chinese approval. The findings help the Chinese government understand what's blocking patients from getting treatments that already exist elsewhere in the world.
WHY IT MATTERSIf you have a rare disease in China, this research directly impacts whether you can access treatments that may already be approved and available in the United States, potentially identifying barriers your doctor or patient advocacy groups can help address.